Search results for "leukemia"

showing 10 items of 976 documents

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate

2017

Key Clinical Message Prompt ophthalmology evaluation and immediate imatinib suspension should be suggested at any time of tyrosine kinase inhibitor therapy in patients with visual deficit, as it may be a clinical manifestation of optic disk edema, and suspension may help in prompt recovery.

Adverse event0301 basic medicinegenetic structuresmedicine.drug_classOptic Disk EdemaLate onsetCase ReportClinical manifestationCase ReportsTyrosine-kinase inhibitor03 medical and health sciences0302 clinical medicinechronic myeloid leukemiatyrosine kinase inhibitorsmedicineIn patientAdverse effectbusiness.industryoptic disk edemaImatinibGeneral Medicineeye diseases030104 developmental biologyImatinib mesylateimatiniboptic nerve edemaAnesthesiaAdverse events030221 ophthalmology & optometrybusinessmedicine.drugClinical Case Reports
researchProduct

Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possible relationship to the effe…

2004

<i>Background:</i> The effects of the A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) agonist IB-MECA were examined in HL-60 leukemia and in its multidrug-resistant variant HL-60R cells. <i>Methods:</i> Cytotoxicity was evaluated by MTS assays and apoptosis by flow cytometry analyses of DNA fragmentation and phosphatidylserine exposure. The mRNAs of A<sub>3</sub>AR and inhibitor of apoptosis proteins (IAPs) were determined by RT-PCR. <i>Results:</i> A<sub>3</sub>AR expression was similar in HL-60 and HL-60R cells. At ≧100 µ<i>M</i>, IB-MECA exhibited strong cytotoxic and apoptotic effects in H…

AgonistProgrammed cell deathAdenosinemedicine.drug_classApoptosisHL-60 CellsBiologyInhibitor of apoptosisInhibitor of Apoptosis ProteinsDrug DiscoverymedicineNeoplasmHumansPharmacology (medical)PharmacologyGeneral Medicinemedicine.diseaseAdenosine A3 receptorFlow CytometryAdenosineDrug Resistance MultipleLeukemiaInfectious DiseasesOncologyBiochemistryApoptosisDrug Resistance NeoplasmA 3 adenosine receptor IB-MECA Apoptosis Multidrug resistance Inhibitor of apoptosis proteinsCancer researchmedicine.drugChemotherapy
researchProduct

Selection and characterization of a novel agonistic human recombinant anti-Trail-R2 minibody with anti-leukemic activity

2009

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising natural anticancer therapeutic agent because through its “death receptors”, TRAIL-R1 and TRAIL-R2, it induces apoptosis in many transformed tumor cells, but not in the majority of normal cells. Hence, agonistic compounds directed against TRAIL death receptors have the potential of being excellent cancer therapeutic agents, with minimal cytotoxicity in normal tissues. Here, we report the selection and characterization of a new single-chain fragment variable (scFv) to TRAIL-R2 receptor isolated from a human phage-display library, produced as minibody (MB), and characterized for the in vitro anti-leukemic tumoricid…

Agonistmedicine.drug_classTRAIL; TRAIL-R2; minibody; anticancer therapyImmunologylymphoma; therapy; recombinant antibodyTRAILApoptosislymphomaCHO CellsCricetulusPeptide LibraryTRAIL-R2CricetinaeImmunoglobulin FragmentmedicineAnimalsHumansImmunology and Allergyrecombinant antibodyanticancer therapyReceptorCytotoxicityImmunoglobulin FragmentsPharmacologytherapyLeukemiaChemistryAnimalChinese hamster ovary cellAntibody-Dependent Cell CytotoxicityminibodyApoptosiIn vitroRecombinant ProteinsReceptors TNF-Related Apoptosis-Inducing LigandCHO CellCell cultureApoptosisImmunologyCancer researchTumor necrosis factor alphaCricetuluHuman
researchProduct

Study of the Expression of Angiogenic Factors and Dopaminergic Receptors: Correlation with ZAP70, CD38 and the Mutational State in Chronic Lymphocyti…

2006

Abstract The angiogenesis is a well known process implicate in the progression of CLL. In this disease has been described an increase of angiogenic and pro-angiogenic factors in serum and angiogenic receptors in B cells, mainly in advances stages. Recently had been known that the agonist of the dopaminergic receptor D2 can inhibit the tumour growth and a possible mechanism mediator is the internalization of VEGFR-2. The aim of this work had been to analyze the expression of the dopaminergic receptors (D1, D2, D3, D4 and D5), the angiogenic receptors and its correlation with the main biological factor implicated in the illness (ZAP-70, CD38 and the mutational status of IgVH/BCL-6). We had de…

Agonistmedicine.medical_specialtymedicine.drug_classAngiogenesisZAP70Chronic lymphocytic leukemiaImmunologyDopaminergicCell BiologyHematologyBiologyCD38medicine.diseaseBiochemistryEndocrinologyDopamine receptorInternal medicinemedicineReceptorBlood
researchProduct

Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T …

2007

In allogeneic hematopoietic stem cell transplantation (AHSCT) graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect are closely but not invariably linked. Thus, harnessing donor lymphocyte mediated GVL immunity and separating it from GVHD is of particular interest. Based on results obtained in murine models we have explored the CD95-mediated activation-induced cell death (AICD) strategy to selectively deplete alloreactivity in human donor T lymphocytes in vitro. Following stimulation of CD3(+) T cells isolated from HLA-A* 0201-positive donors with HLA or minor histocompatibility antigen mismatched hematopoietic or nonhematopoietic cells in the presence of agonistic anti-CD…

AllodepletionLymphocyteApoptosisGraft vs Leukemia EffectHuman leukocyte antigenBiologyEpitopeLymphocyte DepletionImmune systemCell Line TumorMinor histocompatibility antigenmedicineCytotoxic T cellHumansTransplantation Homologousfas ReceptorTransplantationHematopoietic Stem Cell TransplantationFOXP3Hematologymedicine.anatomical_structureLymphocyte TransfusionImmunologyT cell depletionLymphocyte graft engineeringCD8Biology of Blood and Marrow Transplantation
researchProduct

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymp…

2018

Abstract Introduction: T-cell acute lymphoblastic leukemia (T-ALL) accounts for about 20% of pediatric and adult ALL cases. Despite the use of intensive chemotherapy protocols, 25% of children and 50% of adult patients fail to respond or relapse. The 3-years prognosis for these patients is poor and novel treatment options are needed. The targeting of tumor-associated antigens by monoclonal antibodies (mAb) is among the most investigated immune-therapeutic strategies. Accordingly, we developed a new humanized mAb (hUMG1), directed against a heavy glycosylated epitope of CD43 which presents a high reactivity against T-ALL cells. Here we investigated the pre-clinical therapeutic activity and t…

Antibody-dependent cell-mediated cytotoxicitybiologymedicine.diagnostic_testmedicine.drug_classbusiness.industryImmunologyCell BiologyHematologyMonoclonal antibodymedicine.diseaseBiochemistryEpitopeFlow cytometryLeukemiaAntigenCancer researchmedicinebiology.proteinImmunohistochemistryAntibodybusinessBlood
researchProduct

Influence of DNA damage and repair upon the risk of treatment related leukemia

2008

Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) are malignancies occurring after exposure to chemotherapy and/or radiotherapy. Several studies have addressed cumulative dose, dose intensity and exposure to specific agents of preceding cytotoxic therapy in relation to the risk of developing such leukemia. Since only a small percentage of patients exposed to cytotoxic therapy develop t-MDS/AML, it has been suggested that some genetic predisposition may be involved, specifically associated to polymorphisms in certain genes involved in chemotherapy/radiotherapy response - fundamentally genes intervening in drug detoxification and DNA synthesis and repair. A review is made …

Antimetabolites AntineoplasticCancer ResearchDNA RepairDNA repairDNA damagemedicine.medical_treatmentAntineoplastic AgentsBiologyhemic and lymphatic diseasesmedicineGenetic predispositionHumansTopoisomerase II InhibitorsGenetic Predisposition to DiseaseAntineoplastic Agents AlkylatingChemotherapyPolymorphism GeneticDrug detoxificationMyeloid leukemiaNeoplasms Second PrimaryHematologymedicine.diseaseRadiation therapyLeukemiaOncologyImmunologyCancer researchDNA DamageLeukemia & Lymphoma
researchProduct

Antiproliferative and chemomodulatory effects of interferon-γ on doxorubicin-sensitive and -resistant tumor cell lines

1993

Biological agents might offer various therapeutic opportunities in the treatment of cancer, including a direct and/or host-mediated antiproliferative effect and also the possibility to favorably modulate tumor resistance to antineoplastic drugs. We studied the in vitro antiproliferative effects of interferon (IFN)-gamma on the mouse B16 melanoma and Friend erythroleukemia, and the human K562 erythroleukemia, as doxorubicin (DXR)-sensitive and -resistant (multidrug resistant) variants. These effects were marked in B16 melanoma and rather slight in K562 erythroleukemia, without any difference between the DXR-sensitive and -resistant lines. The chemosensitive variant of Friend erythroleukemia …

Antimetabolites AntineoplasticCancer Researchmedicine.medical_treatmentDrug ResistanceMelanoma ExperimentalInterferon-gammaMicechemistry.chemical_compoundInterferonMethionine Sulfoximinehemic and lymphatic diseasesTumor Cells CulturedmedicineAnimalsHumansCytotoxic T cellPharmacology (medical)DoxorubicinButhionine sulfoximineInterferon gammaButhionine SulfoximinePharmacologyGlutathioneFriend murine leukemia virusCytokineOncologychemistryDoxorubicinCell cultureCancer researchLeukemia Erythroblastic AcuteCell Divisionmedicine.drugK562 cellsAnti-Cancer Drugs
researchProduct

Identification of Biphenyl-Based Hybrid Molecules Able To Decrease the Intracellular Level of Bcl-2 Protein in Bcl-2 Overexpressing Leukemia Cells

2009

With the aim of enhancing the structural complexity and diversity of an existing collection of bi- and terphenyl compounds, we synthesized hybrid molecules comprising of spirocyclic ketones (a complexity-bearing core) and bi/terphenyls (privileged fragments). Compounds 1, 3, 4, and 6 showed well-defined activity on apoptosis and differentiation, making them potential leads for development as new anticancer agents and chemical probes to study signaling networks in neoplastic cells.

Antineoplastic AgentsApoptosisHL-60 CellsChemical synthesisStructure-Activity RelationshipLeukemia Myelogenous Chronic BCR-ABL PositiveTerphenyl CompoundsDrug DiscoverymedicineHumansSpiro CompoundsChemistryBiphenyl CompoundsCell DifferentiationBiological activityKetonesmedicine.diseaseIn vitroLeukemiaProto-Oncogene Proteins c-bcl-2BiochemistryApoptosisCell cultureMolecular MedicineTerphenyl CompoundsK562 CellsIntracellularJournal of Medicinal Chemistry
researchProduct

Antimicrobial and antiproliferative activity of Peucedanum nebrodense (Guss.) Strohl.

2003

Abstract Acetone extract of Peucedanum nebrodense (Guss.) Strohl., a rare endemic species from the Madonie mountains (Sicily), was tested in vitro for its antimicrobial activity against bacterial reference strains and antiproliferative activity against K562 (human chronic myelogenous leukemia), HL-60 (human leukemia) and L1210 (murine leukemia) cell lines. The acetone extract showed antiproliferative IC 50 values in the range of 14–0.27 μg/ml.

Antineoplastic AgentsHL-60 CellsBiologyPlant RootsAcetoneMiceAnti-Infective Agentshemic and lymphatic diseasesDrug DiscoverymedicinePeucedanum nebrodenseCoumarins Antimicrobial Antiproliferative activityAnimalsHumansLeukemia L1210PharmacologyTraditional medicinePlant ExtractsBiological activityPlant Components AerialAntimicrobialmedicine.diseaseIn vitroLeukemiaCell cultureK562 CellsPeucedanum nebrodenseCell DivisionChronic myelogenous leukemiaK562 cellsApiaceaeJournal of ethnopharmacology
researchProduct